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INTRODUCTION
Antidepressants are usually the first line 
of treatment for those with moderate 
or severe depression in primary care.1 
In 2014, 57.1 million prescriptions for 
antidepressants were dispensed, more 
than double the number issued 10 years 
earlier (28.2 million in 2004).2 There is 
evidence to suggest that the increase in 
prescribing seen in recent years is largely 
the result of more patients receiving long-
term treatment.3–5 In one fairly recent study, 
47% of patients had been taking the same 
antidepressant for more than 2 years.6
However, many patients do not respond to 
antidepressants.7 In UK primary care, 55% of 
patients who have taken antidepressants for 
at least 6 weeks continue to have significant 
depressive symptoms.8 In the event of 
non-response (or inadequate response) 
to a course of antidepressants, National 
Institute for Health and Care Excellence 
(NICE) guidance suggests switching 
antidepressants (either within or between 
classes), augmenting medication with a drug 
that is not an antidepressant, or combining 
two antidepressants.1 Yet, there is little 
robust evidence for any of these strategies1 
and little is known about how GPs manage 
patients whose depression does not respond 
to treatment with antidepressant medication. 
The CoBalT study was a large multicentre 
randomised trial that investigated the 
effectiveness of cognitive behavioural 
therapy (CBT) as an adjunct to usual 
care for patients with treatment-resistant 
depression (TRD) compared with usual GP 
care.9,10 This paper uses quantitative and 
qualitative data collected during the CoBalT 
trial to describe usual care for primary 
care-based patients with TRD.
METHOD
The CoBalT trial 
The CoBalT study was a randomised 
controlled trial examining the effectiveness 
of CBT as an adjunct to usual care that 
included pharmacotherapy for primary care 
patients with TRD.9–11 Between November 
2008 and September 2010, participants 
were recruited from 73 general practices 
from three UK centres (Bristol, Exeter, 
and Glasgow). Eligible participants were: 




Non-response to antidepressant medication is 
common in primary care. Little is known about 
how GPs manage patients with depression that 
does not respond to medication.
Aim
To describe usual care for primary care patients 
with treatment-resistant depression (TRD).
Design and setting
Mixed-methods study using data from a UK 
primary care multicentre randomised controlled 
trial.
Method
In total, 235 patients with TRD randomised to 
continue with usual GP care were followed up 
at 3-month intervals for a year. Self-report data 
were collected on antidepressant medication, 
number of GP visits, and other treatments 
received. In addition, 14 semi-structured face-to-
face interviews were conducted with a purposive 
sample after the 6-month follow-up and analysed 
thematically.
Results
Most patients continued on the same dose 
of a single antidepressant between baseline 
and 3 months (n = 147/186 at 3 months, 79% 
(95% confidence interval [CI] = 73 to 85%)). 
Figures were similar for later follow-ups (for 
example, 9–12 months: 72% (95% CI = 63 to 
79%). Medication changes (increasing dose; 
switching to a different antidepressant; adding 
a second antidepressant) were uncommon. 
Participants described usual care mainly as 
taking antidepressants, with consultations 
focused on other (physical) health concerns. Few 
accessed other treatments or were referred to 
secondary care. 
Conclusion
Usual care in patients with TRD mainly entailed 
taking antidepressants, and medication changes 
were uncommon. The high prevalence of physical 
and psychological comorbidity means that, when 
these patients consult, their depression may not 
be discussed. Strategies are needed to ensure 
the active management of this large group of 
patients whose depression does not respond to 
antidepressant medication.
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taking antidepressant medication at an 
adequate dose for at least 6 weeks; scored 
≥14 on the Beck Depression Inventory 
(BDI-II) (2nd version);12 and met the ICD-
10 criteria for depression (assessed using 
the Clinical Interview Schedule — Revised 
form.13 Assessment of adherence to 
antidepressants used the Morisky scale,14,15 
with an additional item added to ensure 
that individuals who had missed fewer than 
two consecutive doses were not excluded. 
GPs excluded patients who had: bipolar 
disorder, psychosis, or major alcohol and/or 
substance misuse problems; were unable 
to complete the questionnaires; and were 
pregnant. Individuals who were receiving 
CBT or other psychotherapy or secondary 
care for their depression, who had received 
CBT in the past 3 years, or who were taking 
part in another intervention study were also 
excluded. 
Participants were randomised into one 
of two groups: 1) to continue with usual 
care from their GP; or 2) to receive the 
intervention (12–18 sessions of individual 
face-to-face CBT) in addition to usual care. 
The study found that CBT, given in addition 
to usual care, was effective in reducing 
depressive symptoms and improving quality 
of life in patients with TRD, compared with 
usual care alone.10 This paper focuses on 
the data collected for those individuals 
randomised to continue with usual care 
from their GP. 
Quantitative data
Participants were followed up at 3-month 
intervals for a year. At each follow-up, 
participants were asked whether they 
were still taking antidepressant medication 
and, if so, to provide details (name and 
dose) of the antidepressant medication(s).9 
On two occasions, participants were also 
asked about the number of visits to their GP 
(between baseline and 6-month follow- up; 
and between 6- and 12-month follow-ups). In 
addition, data on other treatments received 
(including computerised/online CBT; 
counselling or other ‘talking therapies’; and 
use of secondary care) were also recorded at 
the 6- and 12-month follow-ups. 
Qualitative interviews
A qualitative study was integrated within 
the CoBalT trial.11 One of its primary 
objectives was to explore trial participants’ 
experiences of usual GP care before and 
during the trial. Patients were invited to take 
part in an interview after completion of their 
primary outcome measures for the trial 
at 6 months post-randomisation. Consent 
to be approached for interview had been 
secured during their baseline assessment 
for the trial.
A purposeful sampling strategy was 
used to ensure interviews were held with 
participants who varied in relation to the trial 
arm, study site (Bristol, Exeter, and Glasgow), 
age, sex, socioeconomic background (based 
on educational attainment, employment 
and housing tenure), and whether they met 
criteria for ‘response’ (the primary outcome, 
defined as at least a 50% reduction in 
depressive symptoms on the BDI-II at 
6 months compared with baseline). 
Face-to-face interviews took place at 
the participant’s home or their GP surgery, 
as preferred. A topic guide was used to 
ensure consistency across the interviews. 
Participants were asked about their 
experiences of depression, what treatments 
and support they had received before and 
during the study, and, specifically, their 
views and use of antidepressants. 
Data analysis
Questionnaire data. The quantitative data 
were analysed using Stata version 13.1. At 
baseline, 3-, 6-, 9-, and 12-month follow-
up, the number of individuals who were 
taking different types of antidepressants 
(or combination therapy) were tabulated. 
Comparisons between data collected at: 
baseline and 3 months; 3 and 6 months; 
6 and 9 months; and 9 and 12 months 
were undertaken in order to determine the 
number of participants who: 
• had continued on the same medication;
• had an increased dose of medication;
How this fits in 
Non-response to antidepressant 
medication is a substantial problem in 
primary care but little is known about how 
GPs manage patients with depression 
that does not respond to such treatment. 
Using data collected as part of the CoBalT 
multicentre randomised controlled trial, it 
was found that changes to antidepressant 
medication are uncommon in primary 
care patients with treatment-resistant 
depression. Many just collect repeat 
prescriptions for their medication, and 
the high prevalence of physical and 
psychological comorbidity means that 
their depression may not be discussed 
during contact with their GP. Therefore, 
it is important that strategies are put in 
place for the active management of the 
large number of patients whose depression 
does not respond to an initial course of 
antidepressant treatment.
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• had switched antidepressant 
medication;
• received a second antidepressant 
(combination therapy) or whose 
treatment was augmented with another 
drug; or
• stopped (or re-started) antidepressants.
Analyses were repeated for the subset 
of participants who reported taking 
antidepressants throughout the 12-month 
follow-up. Descriptive statistics were used to 
summarise the number of GP visits and other 
treatments received during the 12 month 
follow-up (in terms of computerised CBT, 
counselling or ‘talking therapy’, CBT and 
treatment in secondary care). 
Interview data. Participants gave consent 
for their interview to be audiorecorded and 
transcribed verbatim. Data collection and 
analysis took place in parallel, so that earlier 
data collection could inform the focus of later 
interviews, and to enable the researchers to 
establish when data saturation had been 
reached, that is, no new themes emerged 
from the analysis. 
The data were analysed thematically,16 
as this permitted comparisons to be 
made within, and across, the interviews. 
This involved team members reading and 
re-reading transcripts in order to familiarise 
themselves with the data, identify emerging 
themes, and develop a coding frame. This 
coding frame was refined through team 
members independently coding a sample 
of transcripts and then discussing their 
interpretation and coding of the data. 
Once the coding frame had been finalised, 
transcripts were electronically coded using 
the software package ATLAS.ti. Data were 
then systematically analysed using an 
approach based on framework analysis.17 
Using this method, participants’ views about 
specific issues were summarised in tables 
and comparisons then made between the 
accounts of participants of differing age, sex, 
and socioeconomic backgrounds. 
RESULTS
Baseline characteristics of CoBalT 
participants and follow-up rates
In total, 235 patients were randomised to 
continue with usual care from their GP.10 
The mean age was 50 years (SD 11.5 years) 
and most (n = 178, 76%) were female. At 
baseline, their mean BDI-II score was 31.8 
(SD 10.9). Twenty-eight per cent of patients 
(n = 65) met ICD-10 criteria for a severe 
depressive episode and the duration of their 
current episode of depression was at least 
2 years for 60% of patients (n = 140). Eighty-
nine percent (n = 210) had a secondary 
diagnosis of an anxiety disorder based on 
the Clinical Interview Schedule — Revised 
version (CIS-R) and 77% (n = 181) self-
reported a longstanding illness or disability. 
The number followed up with data at 
baseline and 3 months; 3 and 6 months; 
6 and 9 months; and 9 and 12 months 
was 219 (93%), 207 (88%), 191 (81%), and 
181 (77%) respectively. The mean BDI-II 
scores at follow-up have been previously 
published.10 For those in the usual-care 
group included in the present analyses, 
the BDI-II scores at follow-up were: mean 
24.4 (SD 13.1) at 6 months and mean 21.3 
(SD 12.9) at 12 months. 
Self-reported data on use of 
antidepressant medication and other 
health care
At baseline, 214 (91%) of participants in 
the usual-care arm were taking a single 
antidepressant (monotherapy), with 
citalopram and fluoxetine being the two 
most common drugs (Table 1). Most 
patients (n = 152, 71%) had taken this 
medication for more than 12 months. 
Table 1. Antidepressant medications at baseline 
Antidepressant Dose, mg Antidepressant Dose, mg n %
Monotherapy (n = 214)
 Citalopram 20–60    71 30.2
 Fluoxetine 20–60    70 29.8
 Venlafaxine 75–300    18 7.7
 Mirtazapine 30–60    15 6.4
 Paroxetine 20–40    12 5.1
 Dosulepin 150–175    6 2.6
 Sertraline 100–150    6 2.6
 Lofepramine 140–210    5 2.1
 Escitalopram 10–40    3 1.3
 Amitriptyline 150–180    3 1.3
 Duloxetine 60–90    2 0.9
 Trazodone 150–300    2 0.9
 Reboxetine 8    1 0.4
Combination therapy (n = 21)
 Fluoxetine 20–40 Amitriptyline 20–120 9 3.8
 Citalopram 20–50 Amitriptyline 10–150 5 2.1
 Citalopram 20–40 Mirtazapine 15–22.5 2 0.9
 Citalopram 10 Venlafaxine 75 1 0.4
 Fluoxetine 80 Citalopram 20 1 0.4
 Paroxetine 40 Amitriptyline 20 1 0.4
 Sertraline 100 Nortriptyline 100 1 0.4
 Venlafaxine 150 Amitriptyline 225 1 0.4
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Twenty-one individuals (9%) were taking 
two antidepressants (combination therapy), 
though in 12 cases this included low-
dose (<75 mg) amitriptyline (Table 1). 
Most participants continued to take 
antidepressants during the follow-up period 
(Table 2).
Of the 186 patients who were taking a 
single antidepressant at baseline and 
who were followed up at 3 months, the 
majority (n = 147, 79%) continued on the 
same dose of medication at 3 months 
(Table 2, total number on monotherapy = 
number continued on same drug, switched 
antidepressant and changed to combination/
augmented treatment). Figures  were 
similar for the later follow-ups (130 out 
of 163 (80%) at 6 months; 113 out of 149 
(76%) at 9 months; and 103 out of 144 (72%) 
at 12 months). Of those who continued 
on the same antidepressant, only a small 
percentage (9–13%) were taking an 
increased dose of their antidepressant at the 
subsequent follow-up (Table 2). Switches to 
a different antidepressant or the addition of 
a second antidepressant treatment were 
uncommon (Table 2). Most patients who 
were taking two antidepressants at baseline 
continued with combination therapy during 
follow-up (Table 2). 
In the subset of 145 patients who 
completed all the follow-ups and who 
reported taking antidepressants at all time 
Table 3. Other treatments received during follow-up among those in 
the usual-care group
 6-month follow-up 12-month follow-up
Other treatment received  N n % N n %
Used any CBT packages during last 6 months 213 7 3.3 198 3 1.5
Had any counselling or ‘talking therapy’ 213 23 10.8 197 33 16.8 
during the last 6 months
Had CBT during the last 6 months 213 6 2.8 197 12 6.1
0–5 sessions of CBT 213 2 0.9 197 3 1.5
6–8 sessions of CBT  213 2 0.9 197 5 2.5
≥9 sessions of CBT 213 2 0.9 197 4 2.0
Use of hospital or secondary care services because of mental health problems
NHS hospital for an overnight stay 211 0 0 196 3 1.5
Visited Emergency Department 211 3 1.4 196 3 1.5 
for mental health problems
NHS outpatient or community 211 3 1.4 196 12 6.1  
mental health team clinics  
Private hospital or clinics for  211 0 0 196 1 0.5 
mental health problems
CBT = cognitive behavioural therapy.
Table 2. Changes in antidepressant medication taken during follow-up 
   Baseline–3 months 3–6 months 6–9 months 9–12 months 
   (n = 219) (n = 207) (n = 191) (n = 181)
No longer taking antidepressants (already stopped + new stops) 8 14 11 14
Still taking antidepressants   211 191 175 165
Re-started taking antidepressants   0 2 5 2
1st time point 2nd time point Baseline–3 months 3–6 months 6–9 9–12 
     months months 
   (n = 203)a (n = 181)a (n = 170)a (n = 161)a
Monotherapy Continued on same drug 176 156 142 131  
 Same dose 147 130 113 103 
  Increased dose 17 14 15 17  
  Reduced dose 12 12 14 11
 Switched antidepressant 5 2 3 6  
  Within class 1 1 1 2 
  Between class 4 1 2 4
 Combination therapy/augmented 5 5 4 7 
   antidepressant 
  Second antidepressantb 5 5 4 7 
  Non-antidepressant augmenter 0 0 0 0 
Combination therapy Continued on combination therapyb 14 15 15 14  
  Same combination of drugsc 14 15 14 13  
  Different combination 0 0 1 1 
 Change to monotherapy 3 3 6 3 
Missing information on type and/or dose of antidepressant 8 10 5 4 
aNumber of patients with data on type and dose of antidepressant medication among those still taking antidepressants. bIncludes combinations where the second antidepressant is 
low-dose (<75 mg) amitriptyline. cDose of medication may have changed.
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points, 116 (80%) reported taking the same 
medication(s) throughout and 69 (48%) 
reported no change in the dose of their 
medication(s) (further details on the subset 
who took antidepressants throughout 
follow-up are available from the authors 
on request). 
The percentage who switched to a 
different antidepressant or who were taking 
two antidepressants were similar to the 
figures using all available data.
On average, patients visited their GP four 
times between baseline and the 6-month 
follow-up (n = 210; mean 4.1 [SD 3.5]) and on 
a similar number of occasions between 6 and 
12 months (n = 197; mean 4.1 [SD 4.9]). Few 
patients reported using any computerised 
CBT packages during the 12-month follow-
up (Table 3). 
Less than 25% of participants had received 
counselling or ‘talking therapy’ during 
the 12-month follow-up and the number 
receiving CBT was very small (Table 3: n = 4 
had ≥9 sessions of CBT at 12-month follow-
up). 
Few participants had received outpatient 
treatment at an NHS hospital or community 
mental health team clinic (Table 3). 
Characteristics of participants who took 
part in the face-to-face interviews
Interviews with the 14 usual-care 
participants lasted, on average, 51 minutes 
(range: 24–85 minutes). The characteristics 
of those interviewed were similar to 
those who participated in the CoBalT 
trial generally10 (Table 4). Mean age was 
45 years, the majority (71%, n = 10) were 
female, and 57% (n = 8) were home owners. 
All had a secondary diagnosis of an anxiety 
disorder. 
Interview findings
Findings have been presented below under 
headings that relate to the main areas 
explored with participants in relation to 
usual care. They also reflect the main areas 
discussed above during the description of 
the quantitative findings, to aid comparisons 
between the two sets of findings presented 
in this paper.
Participants’ views and experiences of 
antidepressants. Participants’ accounts of 
usual care for their depression described 
how this had mainly entailed taking 
antidepressants. Within the accounts there 
were themes around medication helping 
to manage rather than cure depression, a 
lack of change of antidepressant and active 
monitoring once on medication, and a fear of 
stigmatisation and a perceived dependency 
as a result of taking an antidepressant. 
The role of medication was described as 
maintaining a ‘baseline’ level of functioning 
to prevent further deterioration in mood, 
rather than addressing the underlying 
problem:
‘I think they help me, they sort of give 
me a sort of baseline to work from … it’s 
[the antidepressant] trying to control this 
chemical imbalance or something I’ve got 
in my brain and it sort of helps sort of keep 
it on a level, as if I’m not going to drop too 
far down … I don’t know quite how to explain 
it, but it makes me feel safe.’ (Female, aged 
53 years, Bristol)
Many participants commented that 
they had been taking antidepressants for 
years, often trying multiple antidepressants 
and doses before settling on their current 
regimen. Some patients reported taking 
antidepressant medications primarily for 
indications other than depression, such as 
anxiety disorders and neuropathic pain. All 
the participants reported continuing to take 
the same antidepressant during the trial 
but several people spoke about altering the 
dose of their medication if they felt their 
mood was getting better or worse. 
Almost all the participants mentioned 
not wanting to continue antidepressants 
long term. Reasons included a fear of 
Table 4. Baseline sociodemographic and clinical characteristics of 
participants interviewed (N = 14) 
Baseline characteristic   
Age, years, mean (SD) 45 (11.8)
Female, n (%) 10 (71.4)
Educational background: n (%)  
  GCSE/no formal qualifications 6 (42.9)
  A Levels/higher diploma/degree 8 (57.1)
Employment status: n (%)  
  Paid employment (full/part-time) 6 (42.9)
  Not in employment 5 (35.7)
  Not employed due to ill health 3 (21.4)
Housing: n (%)  
  Homeowner 8 (57.1)
  Tenant/living with relative/other 6 (42.9)
Baseline BDI-II score, mean (SD) 32.6 (7.4)
Duration of depression, >2 years: n (%) 6 (42.9)
Been on current antidepressants for >12 months: n (%) 11 (78.6)
Secondary diagnosis of anxiety disorder: n (%) 14 (100.0)
BDI-II score at 6-month follow-up, mean (SD) 23.2 (9.5)
SD = standard deviation.
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taking something ‘unnatural’, anxiety about 
missing doses, and feeling one ‘ought’ to 
be able to cope without them. However, 
patients were reluctant to reduce or stop 
their medication, even when their mood 
had improved. 
Participants were concerned that their 
symptoms would worsen if they stopped 
medication, and several participants 
described feeling unwell when they missed 
doses or abruptly discontinued medication, 
which they interpreted as evidence of 
ongoing depression:
‘The thing is you only know with these 
things [antidepressants] that they’re doing 
some sort of good when you try to give them 
up and then suddenly you feel twice as bad.’ 
(Male, aged 60 years, Exeter)
‘I tried to come off medication months 
ago and I had a couple of little wobbles 
and stuff so I went back on it.’ (Female, 
aged 26 years, Exeter)
Some participants also explained that 
they were waiting for a less stressful time 
in life, such as retirement, before stopping 
medication. Several participants described 
continuing antidepressants simply because 
their GP continued to issue prescriptions 
and had not discussed stopping medication 
with them. Some seemed reluctant to raise 
the topic of medication reviews during 
consultations, either because they felt it 
was not their role or because they came to 
appointments with multiple medical issues 
that were prioritised over antidepressant 
reviews:
‘The only reason I still take them now is 
because a) I haven’t actually technically 
been told not, you know to come off them, 
and b) I just think it’s not a good idea to just 
suddenly stop them like I did last time.’ 
(Female, aged 26 years, Exeter)
‘I’ll come with my list of things and get 
them done but I would forget unless, I kind 
of … should the GP be doing that, saying 
“let’s have a look at the depressives, let’s 
see what they’ve been on and how long” 
and then bring them in and let’s have a 
go here, and to see whether they’re still 
depressed or whatever or whether it is the 
medication that’s causing it.’ (Male, aged 
60 years, Glasgow)
Participant’s experiences of GP care. The 
participants’ accounts suggested the 
care they received from their GP had not 
changed since they entered the trial. All but 
two participants reported no change in how 
often they saw their GP during the study 
period, and the two individuals who said 
they were attending more frequently did 
so to collect sick notes or to monitor their 
weight. Most visits related to physical health, 
particularly musculoskeletal problems, 
rather than mood. Antidepressants were 
generally collected as repeat prescriptions 
and most participants did not describe 
active review by the GP:
Interviewer: ‘So what care has your GP 
given you? Do you just see them when you 
need more antidepressants or do you …’
Patient: ‘I don’t necessarily see them 
about that. Just get a repeat prescription.’ 
(Female, aged 41 years, Bristol)
‘[I see the GP] once a month only because 
I’m on the diet and he’s weighing me 
once a month. Otherwise it would be once 
whenever I needed a repeat prescription … 
which is normally three monthly.’ (Female, 
aged 39 years, Exeter)
Across the accounts there were themes 
around a lack of time, continuity, and 
expertise. Many patients felt that their GP 
did not have enough time to spend with 
them and described a lack of continuity 
in terms of which GP they saw. Some 
expressed a belief that because GPs are 
‘generalists’ they do not have adequate 
understanding of depression:
‘It’s as quick as they can get you out, write a 
script and out you go again.’ (Female, aged 
51 years, Glasgow)
‘I think GP support is helpful but it is very 
limited and I don’t think they really know 
enough about depression either. Or as much 
as perhaps they ought to considering that 
so many people seem to have depressive 
symptoms.’ (Female, aged 29 years, Bristol)
However, there were exceptions with two 
participants stating that their GP closely 
monitored their mood and offered frequent 
medication reviews and referrals, though 
it was apparent that even patients who felt 
closely monitored remained on a stable 
dose of medication during the trial:
‘She’s been keeping quite a close eye on how 
I am and listening to me, she’s very good 
like that … Each time I see her she says well 
come back and see me such and such and 
we’ll see how you’re going then and we’ll 
discuss again if you want to come down off 
the tablets.’ (Female, aged 53 years, Bristol)
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Experiences of seeking additional care. Very 
few participants said that they had accessed 
secondary care services or psychotherapy 
during the trial. Some participants cited 
barriers to accessing therapy, such as lack 
of local services, long waiting lists, and cost 
(for treatments not available on the NHS). 
Other participants mentioned that attending 
appointments would be difficult due to a 
lack of transport, because they had care 
or work commitments, or were anxious 
about leaving the house. Some participants 
seemed to be struggling with motivation, 
waiting for someone else to suggest therapy, 
or believing that it would not work for them. 
Others were dissuaded from seeking further 
treatment, having previously experienced 
counselling or therapy as unhelpful:
‘I’d got absolutely nowhere, because I mean 
I wasn’t understanding what he was getting 
at and that would make the whole thing 
utterly futile … it was difficult and I could not 
relate what happened during the day to a 
depressive episode.’ (Male, aged 60 years, 
Glasgow)
Other participants mentioned that they 
did not feel the need for psychological 
treatment because their symptoms had 
improved or they did not feel ‘depressed’. In 
addition, many participants described having 
developed their own coping strategies. 
These included accessing complementary 




Most patients whose depression had not 
responded to antidepressants were taking 
a single antidepressant and, over a period 
of 12 months, most continued to take the 
same medication, often at the same dose. 
Switching to a different antidepressant 
or starting a second antidepressant 
(combination therapy) was uncommon. 
Patients reported visiting their GP, on 
average, eight times over the 12-month 
follow-up period. However, the interview 
data suggested that these consultations 
were often for other health problems 
and many patients reported getting their 
antidepressants via repeat prescriptions. 
Use of computerised CBT packages was 
infrequent. Less than 20% of patients 
had received some form of counselling or 
‘talking therapy’ over the 12 months, with 
very few receiving a course of CBT or having 
been referred to secondary care.
Patients recruited to the CoBalT trial had 
severe and chronic depression, often with 
physical and psychological comorbidity. 
Many patients spoke about the fact that 
they had been on antidepressants for years 
and during that time had tried a number 
of different antidepressants. Changes in 
the type of medication were sometimes 
made in response to side effects but not all 
patients were clear about the rationale for 
changing or re-starting a different type of 
medication. Many patients clearly saw their 
depression as a chronic illness — increasing 
or decreasing the dose of their medication in 
response to a worsening or improvement in 
their depression. Antidepressants were not 
seen as the solution by this group but rather 
a way of helping them to manage their 
symptoms. Some patients were unsure as 
to whether the medication was helpful and 
many expressed a desire to stop taking 
antidepressants and wanted help to do this. 
Strengths and limitations
CoBalT was a large multicentre randomised 
trial based in 73 general practices in 
UK primary care. An inclusive definition 
of treatment resistance was used, hence 
patients recruited to CoBalT were likely 
to be representative of those whose 
depression has not responded to treatment 
with antidepressants in primary care. 
The authors used self-reported data on 
antidepressant use that was collected on 
multiple occasions during the 12-month 
follow-up. As such, there were data on what 
patients were taking, rather than making 
assumptions about medication usage based 
on prescription data. Follow-up rates over 
the 12 months were high, with patterns of 
antidepressant medication use similar for 
those who provided data at all time points 
compared with those who provided data only 
at some time points. 
It is important to acknowledge that 
participants in this study were taking part 
in a randomised trial. Therefore, as GPs 
were aware that these individuals had been 
randomised to continue with usual care 
(rather than receive the intervention), it 
was possible that GPs could have been 
more proactive in their management of this 
patient group (performance bias). However, 
there was little evidence of this either in 
terms of the number of GP appointments, 
antidepressant medication taken, or use 
of secondary care when compared with 
those randomised to usual care with the 
intervention group.18 Furthermore, accounts 
of usual care were similar for those who 
received CBT.11 This was a group of patients 
with severe and chronic depression. The 
majority of participants had been taking 
antidepressant medication for more than 
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12 months. The authors did not have data on 
their depression scores when antidepressant 
medication was first prescribed. Participants 
may, therefore, have experienced partial 
response to treatment, and changes to their 
medication may have taken place before 
entry to the trial. Qualitative data indicate 
that the latter had happened in some cases. 
Comparison with existing literature
To the best of the authors’ knowledge, 
there are no previous studies describing 
usual care for primary care-based patients 
whose depression has not responded to 
antidepressant medication. The lack of 
focus on this group in primary care may 
be, in part, because the term ‘treatment-
resistant depression’ is not commonly used 
in primary care and may be thought to 
describe those in secondary care, rather 
than referring to those whose depression 
does not respond, or only partially responds, 
to treatment with medication. Although 
the earliest definition of ‘treatment 
resistance’ was based on non-response 
to at least 4 weeks of antidepressant 
medication,19 later definitions have focused 
on non-response to multiple courses of 
antidepressants.20 Yet, as the authors have 
shown in a previous paper,8 there are many 
patients in primary care who continue to 
have significant depressive symptoms 
following treatment with antidepressants, 
and this inadequate response to treatment 
is an important public health problem. 
There is good evidence for the clinical 
and cost-effectiveness of individual ‘high 
intensity’ CBT10,21 over the long-term but it 
is clearly important that novel interventions 
are evaluated for the treatment of the large 
number of patients whose depression 
does not respond to treatment with 
antidepressant medication. More active 
management of such patients in primary 
care may improve outcomes for this group. 
The 2017/2018 Quality and Outcomes 
Framework (QOF), which ‘rewards practices 
for the provision of quality care’, has only a 
single item for depression (DEP003).22 As 
such, reviews of patients newly diagnosed 
with depression are commonplace but, 
though the current NICE guidelines for 
depression1 encourage review of those 
taking antidepressants, there is no 
requirement to record symptoms and 
no incentive for GPs to actively manage 
depression in the longer term. Indeed, other 
depression items in the QOF were dropped 
in recent years, which may have contributed 
to the lack of active management. This 
contrasts with long-term physical health 
conditions such as diabetes, chronic 
obstructive pulmonary disease (COPD), 
and cardiovascular disease. As an example, 
the QOF requires practices to maintain a 
register of those with diabetes and COPD 
and has, respectively, nine and three 
indicators related to ongoing management. 
As a consequence, the care of long-term 
physical health conditions is much more 
structured and openly discussed. 
A meta-analysis of the effectiveness 
of disease management programmes 
provides support for such programmes for 
depression,23 though a collaborative care 
model for depression evaluated in the UK 
had only modest benefits24 and others have 
highlighted a lack of confidence among 
some GPs in managing patients with 
depression compared with those with long-
term physical conditions.25 A recent report 
from the King’s Fund26 also highlights, in 
line with the authors’ data, the lack of 
follow-up for patients with depression. The 
latter may be one of the most important 
elements of high-quality care for patients 
with depression.27 The latest revisions 
of the NICE depression guidelines, 
currently in draft (https://www.nice.org.uk/
guidance/indevelopment/gid-cgwave0725/
documents), include recommendations to 
review how well treatments are working and 
thus may encourage more active follow-up.
Implications for practice
The NHS mandate28 requires NHS England 
to ensure ‘parity of esteem’ between mental 
and physical health conditions, and to make 
improvements in the way that long-term 
conditions are managed. It is standard 
practice in primary care to have nurse-led 
clinics to review the care of those with long-
term physical conditions such as diabetes, 
COPD, and cardiovascular disease. It is time 
to ensure that equivalent strategies are in 
place for the active management of the 
large number of patients whose depression 
does not improve after an initial course of 
antidepressant treatment. 
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